Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients

被引：0
|
作者：
Klein, U. [1 ]
Liang, E. [1 ]
Vogel, B. [1 ]
Kolbinger, F. [1 ]
Bruin, G. [1 ]
Lloyd, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2013年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1012
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [41] Successful Treatment of Acrodermatitis Continua of Hallopeau with an Anti-IL-17A Agent
    Inoue, Sae
    Watanabe, Rei
    Ishitsuka, Yosuke
    Nakamura, Yoshiyuki
    Fujisawa, Yasuhiro
    Okiyama, Naoko
    Fujimoto, Manabu
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (02)
  • [42] Exploring molecular transformation in psoriatic patients during 84 days of anti-IL-17A treatment
    Bertelsen, T.
    Ljungberg, C.
    Iversen, L.
    Johansen, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S76 - S76
  • [43] Anti-IL-17A therapy improves signs and symptoms in patients with rheumatoid arthritis and seronegative spondylarthritides
    Hueber, W.
    Patel, D.
    Antoni, C.
    Mpofu, S.
    CYTOKINE, 2012, 59 (03) : 543 - 543
  • [44] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    Fox, T.
    Huang, J.
    Papavassilis, C.
    Liang, E.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758
  • [45] Anti IL-17 flared psoriasis in a patient on secukinumab
    Noell, Claire
    McQuade, Brianna
    Gottlieb, Alice
    Rosmarin, David
    DERMATOLOGIC THERAPY, 2017, 30 (04)
  • [46] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    de Vera, A.
    Kolbinger, F.
    Spindeldreher, S.
    Ren, M.
    Bruin, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (09) : 1733 - 1741
  • [47] Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity potential according to human in vitro assays
    Karle, A.
    Spindeldreher, S.
    Kolbinger, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E164 - E164
  • [48] Indigodole E from Strobilanthes cusia exhibits anti-IL-17A effect
    Lee, Chia-Lin
    Wang, Chien-Ming
    Yen, Hung-Rong
    Song, Ying-Chyi
    Chen, Chao-Jung
    NATURAL PRODUCT RESEARCH, 2022, 36 (23) : 5935 - 5939
  • [49] IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
    Blauvelt, Andrew
    Lebwohl, Mark G.
    Bissonnette, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (08) : 1946 - 1953
  • [50] Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis
    Uyttenhove, Catherine
    Sommereyns, Caroline
    Theate, Ivan
    Michiels, Thomas
    Van Snicka, Jacques
    AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 330 - 336
12345